CMS Proposed National Coverage Decision Topic List Exempts Biopharma
This article was originally published in RPM Report
Executive Summary
The Centers for Medicare & Medicaid Services’ new list of “potential” topics for National Coverage Decisions includes 33 separate ideas, most proposed by the public. Not one is directly related to a biopharma topic. CMS’ coverage team swears it remains interested in drug-related coverage issues—but still, this is one list it is nice not to be on.
You may also be interested in...
Drugs Not ‘On Radar’ For Medicare Coverage Review, Official Says
The director of Medicare’s coverage and analysis group says that, at the moment, no biopharma products are being considered for a national coverage determination. Another official says Medicare cannot use comparative effectiveness data in making reimbursement decisions.
The Value of Knowing: CMS Rejects Coverage of Lilly’s Amyvid – Except As Tool For Further Research
CMS is proposing to deny coverage of Lilly’s Alzheimer’s “rule-out” diagnostic Amyvid. The decision is important for biopharma manufacturers for several reasons, both as a demonstration that the agency really will refuse to pay for FDA approved drugs—and for how CMS thinks it can actually use its authority to encourage research on effective AD therapies.
The Zaltrap Price Debate: Less Than Meets The Eye
Sanofi is responding to critics of the Zaltrap price with a 50% discount. Is this a “watershed” moment for cancer drug prices? Probably not. The real test will come when payors resist a price on a drug with a proven therapeutic advantage – and when the drug really matters to the sponsor.